Tempus AI (TEM) said Tuesday that its artificial intelligence-enabled care pathway intelligence platform will now support breast cancer patients.
The company said Tempus Next now addresses five testing gaps tied to breast cancer biomarkers and has been integrated into electronic medical records at Mercy, a provider network.
Tempus said the breast cancer expansion was funded by the company and one or more life sciences sponsors.
Shares of the company were up 1.8% in recent early trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。